Morín-Zaragoza R, Rodríguez-Choreño JD, Morales-Suárez MO, Rodríguez-Almaraz JE

Language: Spanish
References: 18
Page: 154-160
PDF size: 151.13 Kb.

ABSTRACT

Introduction. The results of clinical experience are presented in four months, in 288 patients to evaluate the safety and efficacy of combined treatment with triiodothyronine 75 mg, 8 mg diazepam, 50 mg D-Norpseudoephedrine, atropine 0.36 mg and 16.2 mg aloina. Objective. Show results of drug treatment (as part of the integrated management) short-term (four months) against obesity with the combination of T3, one phenylethylamine, a benzodiazepine, an anticholinergic and an adsorbent in slow release. Results. The results obtained indicate that this drug combination significantly reduces weight (all in kg and percentage), BMI, and that makes mainly at the expense of adipose tissue because less fat (kg and%), the waist circumference and glucose (FPG), with minimal side effects, no statistically significant increase in blood pressure. Conclusion. These updated clinical evidence and underline the effectiveness and safety of short-term drug treatment as part of integrated management (diet and exercise) of obesity.

REFERENCES

1. Instituto Nacional de Salud Pública, ENSANUT 2012 (Encuesta nacional de salud y nutrición, INSP 2012).

2. Cannon CP, Kumar A. Treatment of overweight and obesity: lifestyle, pharmacologic, and surgical options. Clin Cornerstone 2009; 9(4): 55-68.

3. Hauptman J, Lucas Ch, Boldrin M, Collins H. Orlistat in the Long-term treatment of obesity in Primary Care Settings. Arch Fam Med 2000; 9: 160-7.

4. Weintraub M. Long-term weight control: The National Heart, Lung, and Blood Institute Founded Multimodal Intervention Study. Clinical Pharmacology 1992; 581-5.

5. Morín ZR, Lonngi VS, Ponce LM, Alcaraz OR, Barragán DL. Eficacia y seguridad de anfepramona en liberación lenta como tratamiento de obesidad. Revista Mexicana de Cardiología 2007; 18(1): 9-16.

6. Azevedo MR, et al. Experimental hyperthyroidism decreases gene expression and serum levels of adipokines in obesity. The Scientific World Journal 2012. ID: 780890.

7. Landsberg L. Core temperature: a forgotten variable in energy expenditure and obesity? Obesity reviews 2012: 13(Suppl. 2): 97-104.

8. Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nature Review Drug Discovery 2009; 8(4): 308-20.

9. Stanley BG, Urstadt KR, Charles JR, Kee T. Glutamate and GABA in lateral hypothalamic mechanisms controlling food intake. Physiology & Behavior 2011; 104(1): 40-6.

10. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014; 311(1): 74-86.

11. Kim GH, Lin JE, Blomain ES, Waldman S. Anti-obesity pharmacotherapy: new drugs and emerging targets. Clin Pharmacol Ther 2014; 95(1): 53-66.

12. Bray GGA, Ryan DH. Update on obesity pharmacotherapy. Annals of the New York Academy of Sciences 2014; 1311: 1-

13. Issue: The Year in Diabetes and Obesity. 13. Morín ZR, Lonngi VG, Alcaraz OR, Rosas HD. Comparación de dos formulaciones de D-Norpseudoefedrina† y placebo en pacientes obesos tratados durante seis meses. Med Int Mex 2001; 17(6): 260-71.

14. Reichert, et al. Meal replacements and supplementation decrease cardiovascular risk factor. J Complement Integr Med 2013; 10(1): 1-8.

15. Van Gaal LF, Wauters MA, De Leeuw IH. The beneficial effects of modest weight loss on cardiovascular risk factors. Int J Obes Relat Metab Disord 1997; 21(Suppl. 1): S5-S9.

16. Williamson DF1, Pamuk E, Thun M, Flanders D, Byers T, Heath C. Prospective study of intentional weight loss and mortality in overweight white men aged 40-64 years. Am J Epidemiol 1999; 149(6): 491-503.

17. Kang JG, Park Ch. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 2012; 36: 13-25.

18. Castillo Henkel, et al. Influence of Triiodothyronine on the Contractile Effect of D-Nor-Pseudoephedrine. Proc West Pharmacol Soc 2010; 53: 33-6.